Haemonetics Financials

HAE Stock  USD 59.46  1.77  3.07%   
Based on the key indicators related to Haemonetics' liquidity, profitability, solvency, and operating efficiency, Haemonetics may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At present, Haemonetics' Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 198.3 M, whereas Total Stockholder Equity is forecasted to decline to about 546.7 M.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes

Haemonetics Balance Sheet Chart

At present, Haemonetics' Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 198.3 M, whereas Total Stockholder Equity is forecasted to decline to about 546.7 M.
Key indicators impacting Haemonetics' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Net Profit Margin0.08340.0898
Significantly Down
Slightly volatile
Return On Assets0.06940.0535
Significantly Up
Slightly volatile
Return On Equity0.110.1225
Moderately Down
Slightly volatile
Debt Equity Ratio0.880.8415
Sufficiently Up
Slightly volatile
Current Ratio3.212.5597
Significantly Up
Slightly volatile
The financial analysis of Haemonetics is a critical element in measuring its lifeblood. Investors should carefully consider Haemonetics' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.

Cash And Equivalents

225.89 Million

  
Build AI portfolio with Haemonetics Stock
Understanding current and past Haemonetics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Haemonetics' financial statements are interrelated, with each one affecting the others. For example, an increase in Haemonetics' assets may result in an increase in income on the income statement.

Haemonetics Earnings Geography

Please note, the presentation of Haemonetics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Haemonetics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Haemonetics' management manipulating its earnings.

Haemonetics Stock Summary

Haemonetics competes with Inspira Technologies, Tenon Medical, Biomerica, Heart Test, and STRATA Skin. Haemonetics Corporation, a healthcare company, provides medical products and solutions. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts. Haemonetics Corp operates under Medical Instruments Supplies classification in the United States and is traded on New York Stock Exchange. It employs 2821 people.
Specialization
Health Care, Health Care Equipment & Services
InstrumentUSA Stock View All
ExchangeNew York Stock Exchange
ISINUS4050241003
Business Address125 Summer Street,
SectorHealth Care Equipment & Supplies
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.haemonetics.com
Phone781 848 7100
CurrencyUSD - US Dollar

Haemonetics Key Financial Ratios

Haemonetics Key Balance Sheet Accounts

202120222023202420252026 (projected)
Total Assets1.9B1.9B2.2B2.5B2.8B3.0B
Other Current Liab121.8M145.9M185.6M164.2M188.8M198.3M
Net Debt521.3M481.4M629.0M918.0M1.1B1.1B
Retained Earnings202.4M253.2M360.5M352.2M405.0M285.0M
Accounts Payable58.4M63.9M73.4M67.0M77.0M80.9M
Cash259.5M284.5M178.8M306.8M352.8M370.4M
Net Receivables159.4M179.1M206.6M202.7M233.1M123.7M
Inventory293.0M259.4M317.2M365.1M419.9M440.9M
Other Current Assets44.1M46.7M66.3M60.4M69.5M52.6M
Total Liab1.1B1.1B1.2B1.6B1.9B2.0B
Total Current Assets756.0M769.7M768.9M935.0M1.1B1.1B
Short Term Debt221.3M11.8M10.2M303.6M349.1M366.5M
Intangible Assets310.3M275.8M406.1M455.7M524.1M550.3M
Common Stock511K504K508K482K554.3K423.5K
Other Assets67.7M58.8M1.01K1.2K1.1K
Long Term Debt559.4M754.1M797.6M921.2M1.1B1.1B
Good Will467.3M466.2M565.1M604.3M694.9M729.7M
Net Tangible Assets243.4M(100.3M)(28.1M)76.0M68.4M65.0M
Long Term Debt Total559.4M754.1M797.6M921.2M1.1B1.1B
Capital Surpluse572.5M594.7M634.6M523.3M601.8M532.6M

Haemonetics Key Income Statement Accounts

202120222023202420252026 (projected)
Interest Expense17.1M14.6M13.0M9.7M11.2M13.7M
Total Revenue993.2M1.2B1.3B1.4B1.6B1.6B
Gross Profit530.8M622.9M711.9M778.5M895.3M940.1M
Operating Income80.8M156.0M164.9M221.8M255.1M267.8M
Ebit105.2M167.2M206.8M247.1M284.2M298.4M
Ebitda191.7M252.0M295.5M356.0M409.4M429.9M
Net Income43.4M115.4M117.6M167.7M192.8M202.5M
Cost Of Revenue462.4M545.8M597.1M582.3M669.6M336.1M
Income Before Tax63.6M141.4M151.9M212.1M243.9M256.1M
Income Tax Expense20.3M26.0M34.3M44.4M51.1M53.6M
Research Development55.2M58.6M63.0M69.4M79.8M83.8M
Tax Provision20.3M26.0M34.3M44.4M51.1M53.6M
Interest Income17.1M14.6M13.0M9.7M11.2M13.2M
Net Interest Income(17.1M)(14.6M)(13.0M)(9.7M)(8.8M)(9.2M)

Haemonetics Key Cash Accounts

202120222023202420252026 (projected)
Change To Inventory24.3M30.8M(60.1M)(64.7M)(58.2M)(55.3M)
Change In Cash67.2M25.0M(105.7M)128.0M147.2M154.5M
Free Cash Flow75.8M162.9M115.5M142.4M163.8M172.0M
Depreciation97.7M93.3M97.2M115.6M132.9M139.6M
Other Non Cash Items16.9M8.5M24.4M(24.0M)(27.6M)(26.2M)
Capital Expenditures96.5M110.2M66.3M39.3M45.2M54.0M
Net Income43.4M115.4M117.6M167.7M192.8M202.5M
End Period Cash Flow259.5M284.5M178.8M306.8M352.8M370.4M
Change To Netincome64.0M4.7M46.3M36.2M41.6M40.4M
Change Receivables18.9M44.1M(35.0M)(24.4M)(28.1M)(26.7M)
Net Borrowings(17.5M)269.3M37.8M447.3M514.4M540.1M
Investments(86.3M)(143.8M)(322.4M)(161.9M)(145.7M)(153.0M)

Haemonetics Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Haemonetics's current stock value. Our valuation model uses many indicators to compare Haemonetics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Haemonetics competition to find correlations between indicators driving Haemonetics's intrinsic value. More Info.
Haemonetics is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers reporting about  0.33  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Haemonetics is roughly  2.99 . At present, Haemonetics' Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Haemonetics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Most indicators from Haemonetics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Haemonetics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haemonetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.At present, Haemonetics' Sales General And Administrative To Revenue is projected to increase slightly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 2.1 B, whereas Enterprise Value Over EBITDA is forecasted to decline to 10.96.
 2023 2024 2025 2026 (projected)
Gross Profit711.9M778.5M895.3M940.1M
Total Revenue1.3B1.4B1.6B1.6B

Haemonetics fundamental ratios Correlations

-0.83-0.82-0.74-0.81-0.25-0.09-0.79-0.29-0.69-0.79-0.810.04-0.79-0.31-0.77-0.81-0.09-0.57-0.82-0.66-0.85-0.73-0.8-0.170.3
-0.830.960.950.880.560.380.930.380.910.880.990.040.880.630.960.960.230.790.980.860.980.710.970.49-0.41
-0.820.960.910.90.360.210.990.210.820.820.96-0.050.820.490.970.960.10.691.00.850.930.770.960.43-0.2
-0.740.950.910.840.510.380.890.220.930.820.94-0.150.820.610.920.930.050.830.940.90.920.640.90.43-0.31
-0.810.880.90.840.310.220.860.180.80.840.86-0.160.840.470.790.870.040.650.90.780.890.950.830.38-0.25
-0.250.560.360.510.310.790.30.710.640.520.550.320.520.870.430.460.570.640.410.440.570.120.510.62-0.8
-0.090.380.210.380.220.790.20.40.570.210.390.040.210.810.250.30.410.630.250.350.340.050.270.82-0.7
-0.790.930.990.890.860.30.20.150.770.740.95-0.080.740.450.970.940.070.660.980.820.880.740.940.45-0.12
-0.290.380.210.220.180.710.40.150.330.410.380.660.410.490.240.180.690.090.230.220.370.120.410.16-0.52
-0.690.910.820.930.80.640.570.770.330.820.890.010.820.750.820.870.280.880.860.820.920.60.820.58-0.54
-0.790.880.820.820.840.520.210.740.410.820.830.071.00.550.780.810.170.660.840.780.940.730.810.25-0.46
-0.810.990.960.940.860.550.390.950.380.890.830.030.830.60.970.950.230.770.980.860.950.690.980.51-0.37
0.040.04-0.05-0.15-0.160.320.04-0.080.660.010.070.030.070.130.0-0.080.65-0.23-0.05-0.190.04-0.170.110.07-0.23
-0.790.880.820.820.840.520.210.740.410.821.00.830.070.550.780.810.170.660.840.780.940.730.810.25-0.46
-0.310.630.490.610.470.870.810.450.490.750.550.60.130.550.520.570.450.690.530.560.650.290.520.69-0.66
-0.770.960.970.920.790.430.250.970.240.820.780.970.00.780.520.950.130.710.980.850.910.610.960.44-0.22
-0.810.960.960.930.870.460.30.940.180.870.810.95-0.080.810.570.950.080.820.970.810.950.710.930.49-0.36
-0.090.230.10.050.040.570.410.070.690.280.170.230.650.170.450.130.080.110.11-0.010.22-0.030.280.41-0.48
-0.570.790.690.830.650.640.630.660.090.880.660.77-0.230.660.690.710.820.110.730.70.80.430.680.66-0.64
-0.820.981.00.940.90.410.250.980.230.860.840.98-0.050.840.530.980.970.110.730.870.950.760.960.44-0.24
-0.660.860.850.90.780.440.350.820.220.820.780.86-0.190.780.560.850.81-0.010.70.870.830.640.80.36-0.2
-0.850.980.930.920.890.570.340.880.370.920.940.950.040.940.650.910.950.220.80.950.830.730.920.43-0.48
-0.730.710.770.640.950.120.050.740.120.60.730.69-0.170.730.290.610.71-0.030.430.760.640.730.680.25-0.1
-0.80.970.960.90.830.510.270.940.410.820.810.980.110.810.520.960.930.280.680.960.80.920.680.44-0.31
-0.170.490.430.430.380.620.820.450.160.580.250.510.070.250.690.440.490.410.660.440.360.430.250.44-0.51
0.3-0.41-0.2-0.31-0.25-0.8-0.7-0.12-0.52-0.54-0.46-0.37-0.23-0.46-0.66-0.22-0.36-0.48-0.64-0.24-0.2-0.48-0.1-0.31-0.51
Click cells to compare fundamentals

Haemonetics Account Relationship Matchups

Haemonetics fundamental ratios Accounts

202120222023202420252026 (projected)
Total Assets1.9B1.9B2.2B2.5B2.8B3.0B
Other Current Liab121.8M145.9M185.6M164.2M188.8M198.3M
Net Debt521.3M481.4M629.0M918.0M1.1B1.1B
Retained Earnings202.4M253.2M360.5M352.2M405.0M285.0M
Accounts Payable58.4M63.9M73.4M67.0M77.0M80.9M
Cash259.5M284.5M178.8M306.8M352.8M370.4M
Net Receivables159.4M179.1M206.6M202.7M233.1M123.7M
Inventory293.0M259.4M317.2M365.1M419.9M440.9M
Other Current Assets44.1M46.7M66.3M60.4M69.5M52.6M
Total Liab1.1B1.1B1.2B1.6B1.9B2.0B
Total Current Assets756.0M769.7M768.9M935.0M1.1B1.1B
Short Term Debt221.3M11.8M10.2M303.6M349.1M366.5M
Intangible Assets310.3M275.8M406.1M455.7M524.1M550.3M
Common Stock511K504K508K482K554.3K423.5K
Other Assets67.7M58.8M1.01K1.2K1.1K
Long Term Debt559.4M754.1M797.6M921.2M1.1B1.1B
Good Will467.3M466.2M565.1M604.3M694.9M729.7M
Net Tangible Assets243.4M(100.3M)(28.1M)76.0M68.4M65.0M
Long Term Debt Total559.4M754.1M797.6M921.2M1.1B1.1B
Capital Surpluse572.5M594.7M634.6M523.3M601.8M532.6M

Haemonetics Thematic Clasifications

Haemonetics is part of several thematic ideas from Obamacare Repeal to Baby Boomer Prospects. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic Ideas

Haemonetics February 10, 2026 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Haemonetics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Haemonetics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Haemonetics based on widely used predictive technical indicators. In general, we focus on analyzing Haemonetics Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Haemonetics's daily price indicators and compare them against related drivers.

Complementary Tools for Haemonetics Stock analysis

When running Haemonetics' price analysis, check to measure Haemonetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Haemonetics is operating at the current time. Most of Haemonetics' value examination focuses on studying past and present price action to predict the probability of Haemonetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Haemonetics' price. Additionally, you may evaluate how the addition of Haemonetics to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
CEOs Directory
Screen CEOs from public companies around the world
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges